Article

Ursolic acid derivative UA312 ameliorates ionizing radiation-induced cardiotoxicity and neurodevelopmental toxicity in zebrafish via targeting chrna3 and grik5

Fei-fei Xu1, Yue Shang1, Hui-qiang Wei1, Wei-ying Zhang2, Li-xing Wang3, Tong Hu3, Shu-qin Zhang1, Yan-li Li1, Hai-hua Shang1, Wen-bin Hou1, Wen-feng Gou1, Sai-jun Fan1, Yi-liang Li1
1 Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China
2 Department of Biochemistry and Molecular Biology, College of Life Sciences, State Key Laboratory of Medicinal Chemical Biology, Tianjin Key Laboratory of Protein Sciences, Nankai University, Tianjin 300071, China
3 Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, China
Correspondence to: Wen-feng Gou: gouwenfeng@irm-cams.ac.cn, Sai-jun Fan: fansaijun@irm-cams.ac.cn, Yi-liang Li: liyiliang@irm-cams.ac.cn,
DOI: 10.1038/s41401-025-01564-0
Received: 12 December 2024
Accepted: 8 April 2025
Advance online: 28 April 2025

Abstract

The biological damage caused by ionizing radiation (IR) depends not only on the time and doses of exposure to tissue components but also on the developmental state of the cells. Currently, amifostine is the only radiation-protective agent used for clinical indications related to radiation therapy, but this compound has multiple drawbacks including high toxicity, short half-life and no protective effect on the nervous system. Ursolic acid (UA), a natural pentacyclic triterpenoid that exhibits multiple protective effects including anti-inflammatory, anticarcinogenic, and antioxidant effects. Due to its poor solubility and bioavailability, UA is mostly administered with liposomes. In this study we investigated the impact of UA312, an optimized derivative of UA, on radiation-induced developmental toxicity in zebrafish embryos and larvae. Embryo and larvae survival were observed at 4, 24, 48, and 72 hpf. UA312 was administered at 3 hpf, while embryos were irradiated with 6 Gy of γ-irradiation (dose rate: 0.88 Gy/min) at 4 hpf, then the embryos were moved to a fresh buffer. We determined that 40 µM of UA312 was a safe concentration for zebrafish embryos and larvae. We found that treatment with UA312 (40 µM) restored IR-induced early developmental dysplasia of the zebrafish embryos and larvae. Transcriptomic analysis revealed that exposure to IR inhibited multiple pathways related to neurodevelopment and cardiomyocyte function in zebrafish, which were validated by assessing abnormal cardiac morphology, variations in neurotransmitter levels and alterations in locomotor behavior; and that UA312 treatment ameliorated these alterations. We demonstrated that UA312 treatment significantly reversed the related signaling pathways by targeting chrna3 and grik5. In conclusion, this study identified a promising radioprotective drug, UA312, which alleviates IR-induced cardiotoxicity and neurodevelopmental toxicity in zebrafish by targeting chrna3 and grik5. UA312 may be developed as a novel radioprotective agent against acute IR damage in humans.
Keywords: ionizing radiation; UA312; radioprotective agent; myocardial activity; neurotoxicity; zebrafish

Article Options

Download Citation

Cited times in Scopus